Terms of Use

Welcome to www.angiodynamics.com, AngioDynamics' United States web site (the Site).

Use of Internet Site. The information provided on this Site is for general informational and educational purposes only. Certain sections of this Site are intended for particular audiences including AngioDynamics' employees, customers and shareholders, as well as members of the health care community and the general public. Please carefully review these Terms of Use (Terms). For purposes of these Terms, AngioDynamics is referred to as AngioDynamics, us, we, etc. Your use of this Site constitutes your acceptance of these Terms without limitation or qualification. If you do not agree to abide by all of the provisions contained in these Terms, you must not use or access the Site. AngioDynamics may make changes to these Terms, which will be posted to this page and will become effective immediately upon posting. Please review the Terms of Use each time you visit this Internet site.

Content. AngioDynamics will use reasonable efforts to include up-to-date and accurate information in this Site, but makes no representations, warranties, or assurances as to the accuracy, currency or completeness of the information provided. You agree that access to and use of this Site and the content hereof is at your own risk. All information on this Site is provided "AS IS." WITHOUT LIMITING ANY OF THE TERMS OF THIS AGREEMENT, IN NO CASE SHALL ANGIODYNAMICS BE LIABLE IN RESPECT OF THE INFORMATION ON THIS SITE OR ANY USE THEREOF, FOR ANY SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES BASED UPON BREACH OF CONTRACT, NEGLIGENCE, STRICT LIABILITY, OR ANY OTHER LEGAL THEORY. THESE TERMS MAY NOT BE ALTERED, AMENDED, REPLACED, SUBSTITUTED OR RESCINDED BY ANY EMPLOYEE, AGENT, INDEPENDENT CONTRACTOR OR CONSULTANT OF ANGIODYNAMICS. ANY SUCH ALTERATION, AMENDMENT, REPLACEMENT, SUBSTITUTION OR RESCISSION SHALL NOT BE BINDING UPON ANGIODYNAMICS OR ITS AFFILIATES. AngioDynamics also assumes no responsibility, and shall not be liable for, any damages to, or viruses that may infect, your computer equipment or other property on account of your access to, use of, browsing in the Site, or your downloading of any materials, data, text, images, video, or audio from the Site.

Copyrights and Trademarks. AngioDynamics, the AngioDynamics logo, Navilyst Medical, the Navilyst Medical logo, Abscession, Acceler-8, Accu-Vu, Acculis, Angioflush, AngioOptic, Angio-Sac, AngioVac, Avenue, Benephit, BioFlo, the BioFlo seal, Blue Silk, Charter, Circle C, Compensator, Crystaline, Curved Tip, DuraFlow, DuraMax, Durathane, Duration, Dynamic-Flow, EMBARC, Embosafe, Engineered for Excellence, Engineered for Life, Essentials, Evenmore, EVLT, Exact-Length, EXODUS, FLEXCIL, Flow-Thru Hub, Fluoromax, Glyce, Hemo-Lock, Hydro-Tip, Infuse-A-Port, Intelliflow, LifeGuard, LifeJet, LifePort, LifeValve, Mariner, Maximizing VenaCure Potential, Mini Stick, Mini Stick II, Morpheus, MORSE, NAMIC, NanoBurst, NanoKnife, the NanoKnife logo, , NanoRay, NeoStar, NeverTouch, NeverTouch Direct, Nit Vu, Omni, One Step, Optiguide, Option 125, PASV, PeelPro, PERCEPTOR, Precision 980, PRO, Profiler, Protection Station, Pulse Spray, QuickStic, Rita, Saver-7, Sheath-Lok, Smart, Smart Angle, Smart Port, Smart Taper, Snap-Lock, Soft-Vu, SOS Omni, SOSA, SpeedLyser, Spotlight OPS, Squeeze Contrast Controller, StarBurst, Super-Radiopaque, Sulis, TD2, The Greatest Experience in Eliminating Varicose Veins, The Grip, The Power of PASV, Thermopad, TitanPort, Tre-Sheath, Triumph-1, Uni*fuse, Uniblate, VascPak, Vault, VAXCEL, VenaCure, VenaCure EVLT, the VenaCure logo, the VenaCure EVLT logo, VIP VenaCure in Practice, VOLTA, Vortex, Workhorse and XCELA are trademarks and/or registered trademarks of AngioDynamics, Inc., an affiliate or a subsidiary. All of the trademarks, service marks and logos displayed on this Site are registered and unregistered trademarks of AngioDynamics, its affiliates or subsidiaries, or third parties who have licensed their trademarks to AngioDynamics or one of its affiliates or subsidiaries. In addition, all content, including but not limited to text, software, music, sound, photographs, video, graphics or other material contained on this Site or in commercially produced information presented to you through the Site by AngioDynamics, its affiliates or AngioDynamics' third party licensors (Content) is protected by copyright, patents or other proprietary agreements and laws and you are only permitted to use Content as expressly authorized by AngioDynamics, its affiliates or its licensors. Nothing contained herein transfers any right, title, or interest in the Site or the Content to you.

Medical Information. The information provided by this Site is not intended nor is implied to be a substitute for professional medical advice. Always seek the advice of your physician or other qualified health care provider prior to starting any new treatment or with any questions you may have regarding a medical condition. We may also include certain information, reference guides and databases intended for use by licensed medical professionals. These tools are not intended to give professional medical advice. Physicians and other health care providers should always exercise their own clinical judgment for any given situation.

Physicians. AngioDynamics may, through this Site, assist you in searching for or identifying a physician or clinic in your area able to treat a certain condition. In such cases, we do not have any ownership or direct financial interest in any of the specific physicians or clinics listed and do not endorse, certify or recommend any of these physicians or clinics. We do not guarantee or makes any warranties, express or implied, as to the quality of medical advice or care given by any physician or clinic.

Privacy. AngioDynamics respects the privacy of its Site users. Please refer to AngioDynamics' Privacy Policy that explains users' rights and responsibilities with respect to information that is disclosed on this Site.

Non-Confidential Information. Subject to any applicable terms and conditions set forth in our Privacy Policy, any communication or other material that you send to us through the internet, or post on this Site by electronic mail or otherwise, such as any questions, comments, suggestions or the like, is and will be deemed to be non-confidential and AngioDynamics shall have no obligation of any kind with respect to such information. AngioDynamics shall be free to use any ideas, concepts, know-how or techniques contained in such communication for any purpose whatsoever, including but not limited to, developing, manufacturing and marketing products. In the event of any such usage, you agree that AngioDynamics shall have no obligation to you, including those of a monetary nature.

Third Party Internet Sites and Links. The Site may provide links to web sites operated by AngioDynamics outside of the U.S. as well as web sites operated by third parties. Please refer to the separate terms of use, privacy policies, and other rules posted on these linked sites before you use them. Third party links are provided merely as a convenience to you, and the inclusion of any link does not imply affiliation or endorsement by AngioDynamics. AngioDynamics does not review, monitor or check the accuracy of content published on third party sites, and is not responsible for the availability of, and content provided on, third party sites. Similarly, this Site may be accessed from third party links over which AngioDynamics has no control. ANGIODYNAMICS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND AS TO THE ACCURACY, CURRENCY, OR COMPLETENESS OF ANY CONTENT OR INFORMATION CONTAINED IN SUCH INTERNET SITES AND SHALL HAVE NO LIABILITY FOR ANY DAMAGES OR INJURIES OF ANY KIND ARISING FROM SUCH CONTENT OR INFORMATION. If you choose to purchase any products or services from a third party, your relationship is directly with the third party and AngioDynamics is not responsible for any loss or damage of any sort you may incur from dealing with any third party. Third party web sites may contain information about uses of products that have not been approved or cleared by the U.S. Food and Drug Administration. AngioDynamics does not endorse the off-label use of any of our products.

Availability of Products. AngioDynamics' products referred to on this Site may not be available for sale in all countries. We make no representation as to the availability of a particular product in a particular country. For the availability of a particular product in your country, please contact us.

Forward Looking Statements. This Site includes "forward-looking statements" intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Investors can identify these statements by the fact that they do not relate strictly to historical or current facts. These statements contain words such as "expect," "reaffirm," "anticipate," "plan," "believe," "estimate," "may," "will," "predict," "project," "might," "intend," "potential," "could," "would," "should," "estimate," "seek," "continue," "pursue," or "our future success depends," or the negative or other variations thereof or comparable terminology, are intended to identify such forward-looking statements. In particular, they include statements relating to, among other things, future actions, strategies, future performance and future financial results of AngioDynamics. These forward-looking statements are based on current expectations and projections about future events.

Investors are cautioned that forward-looking statements are not guarantees of future performance or results and involve risks and uncertainties that cannot be predicted or quantified and, consequently, the actual performance or results of AngioDynamics may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to, the factors described from time to time our reports filed with the SEC, including our Form 10-K for the fiscal year ended May 31, 2009, financial community and rating agency perceptions of AngioDynamics; the effects of economic, credit and capital market conditions on the economy in general, and on medical device companies in particular; domestic and foreign health care reforms and governmental laws and regulations; third-party relations and approvals, technological advances and patents attained by competitors; and challenges inherent in new product development, including obtaining regulatory approvals. In addition to the matters described above, our ability to develop products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, the outcome of pending patent litigation, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, and the effects on pricing from group purchasing organizations and competition and our ability to integrate purchased businesses, may affect the actual results achieved by AngioDynamics.

Any forward-looking statements are made pursuant to the Private Securities Litigation Reform Act of 1995 and, as such, speak only as of the date made. AngioDynamics disclaims any obligation to update the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date stated.

Export Restrictions/Legal Compliance. AngioDynamics administers and controls this Site from within the United States of America. You may not access, download, use or export the Site or its content in violation of U.S. export laws or regulations, or in violation of any other applicable laws or regulations.

No Reproduction of the Site. Your right to use the Site is personal to you. You agree not to reproduce, duplicate, copy, sell or resell the Site, without the express written consent of AngioDynamics.

Indemnity. You agree to indemnify, defend and hold AngioDynamics, its subsidiaries, affiliates, shareholders, directors, officers, employees and agents, harmless from any claim, demand, liability, expense, or loss, including reasonable attorneys' fees, made by any third party due to or arising out of, or in any way connected with your use of or access to the Site or your violation of these Terms.

Governing Laws. These Terms of Use and your use of this Internet site shall be governed by the laws of the United States of America and the State of New York without regard to its conflicts of laws principles. Any legal action or proceeding related to this Internet site shall be brought exclusively in a federal or state court of competent jurisdiction sitting in New York.

Miscellaneous. If any provision of these Terms of Use is held to be unlawful, void or unenforceable, then such provision shall be severable without affecting the enforceability of all remaining provisions. AngioDynamics reserves the right to alter or delete materials from this Internet site at any time at its discretion. AngioDynamics' failure to act with respect to any breach by you does not constitute a waiver of our right to act with respect to subsequent or similar breaches. Nothing contained in these Terms shall be deemed to constitute either party as the agent or representative of the other party, or both parties as joint venturers or partners for any purpose.

Sign up for e-news

AngioDynamics Reports 2015 Second Quarter Financial Results

  • Second Quarter Fiscal 2015 Net Sales increased 4% to $92.1 million; 5% sales growth excluding supply agreement
  • GAAP EPS of $0.04; Non-GAAP adjusted net income of $0.17 per share, a 21% YOY increase
  • EBITDA of $11.9 million; Adjusted EBITDA of $15.9 million, a 18% YOY increase
  • Company raises full-year adjusted EPS guidance to $0.66-$0.72

ALBANY, N.Y., Jan. 8, 2015 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today reported financial results for the second quarter ended November 30, 2014.

"The strong sales momentum we established last fiscal year continued in the second quarter of FY15 as net sales growth, excluding the supply agreement, reached the high end of our expectation at 5%. Cost savings initiatives and restructuring actions enabled us to realize operating margin expansion leading to earnings per share (non-GAAP) growth of 21% to $0.17 cents per share compared to last year's fiscal second quarter," commented Joseph M. DeVivo, President and Chief Executive Officer. "Our three core businesses each made a positive contribution to our strong performance, marking the seventh consecutive quarter for year-over-year sales growth. Oncology/Surgery produced strong 9% net sales growth and was a key driver for our International business. Our Vascular Access business also posted an impressive 9% increase, fueled by the continued strong performance of our BioFlo platform. Today, BioFlo PICCs represent nearly 60% of our total PICC volume, while our BioFlo offerings in ports and dialysis reached double-digit shares of those product categories in the quarter. Peripheral Vascular grew 1% as it anniversaried an impressive quarter last year, and our fast growing AngioVac technology grew 46% in the quarter as we continue to penetrate the thromboembolism market opportunity. Based on the Company's execution and the performance of our growth drivers in the first half fiscal year 2015, we believe we are extremely well positioned to continue this strong momentum in the second half of Fiscal 2015 to deliver increased net sales, margin expansion and profitability to our shareholders."

Q2 FY15 Financial Results

Net sales of $92.1 million increased 4% compared with last year's second quarter net sales of $88.6 million. Excluding the planned wind-down of the supply agreement with Boston Scientific (BSC), second quarter sales were up 5% to $91 million compared to $86.9 million in last year's second quarter. The following sales comparisons exclude the BSC supply agreement.

Peripheral Vascular net sales in the second quarter increased 1% to $49.4 million compared to $48.8 million in the prior year period. Vascular Access net sales grew 9% to $28 million compared to $25.6 million in the year ago quarter. Oncology/Surgery net sales of $13.6 million increased 9% compared to $12.6 million in the year ago quarter. Net sales in the U.S. rose 4% to $72.1 million from $69.5 million in the prior year period. International net sales grew 9% to $19 million from $17.5 million in last year's second quarter.

The Company's net income was $1.3 million, or $0.04 on a per share basis, compared to a net loss of $0.3 million, or $0.01 on a per share basis, a year ago. Excluding the items shown in the attached quarterly non-GAAP reconciliation table, adjusted net income was $6.2 million, or $0.17 per share, for the second quarter compared to net income of $4.9 million, or $0.14 per share, for the year ago quarter, representing a 21% increase.

Second quarter EBITDA grew to $11.9 million, or $0.33 per share, compared to $8.6 million, or $0.24 per share, in the year ago period. Adjusted EBITDA, excluding the items shown in the attached reconciliation table, was $15.9 million, or $0.44 per share, compared to $13.5 million, or $0.38 per share, in the year ago comparable period, representing a 18% increase.

At November 30, 2014, cash and investments were $16.6 million and debt was $155.2 million.

Recent Events

  • The Company's average daily trading volume tripled from approximately 100,000 shares to 300,000 shares after it was added to the S&P SmallCap 600 Index and the GICS Life & Health Insurance sub-industry index after the close of trading on Monday, October 20, 2014. The S&P SmallCap 600 Index consists of 600 small capitalization stocks defined as companies with market capitalizations between $400 million and $1.8 billion. Other criteria include financial viability, stock trading liquidity, public float size and corporate governance structure.
  • AngioDynamics' NanoKnife system received OPS procedure classification codes from the German Ministry of Health. Eleven new OPS Codes were introduced covering bile ducts, bone, liver, lung, stomach, adrenal gland, kidney, esophagus, prostate pancreas and rectum. This process is the first step in securing reimbursement for new medical technologies in Germany. Additionally, the Company received a DRG code for NanoKnife in the Pancreas in the Netherlands.
  • The Company signed an agreement, effective January 1, 2015, with HealthTrust covering PICC (peripherally inserted central catheter) products. Under the terms of the agreement, AngioDynamics' entire PICC portfolio, including its thromboresistant BioFlo PICC product line and Celerity tip location system, became available to HealthTrust members.
  • The Company received a Warning Letter from the FDA relating to observations noted during FDA's inspection of the Company's Navilyst Medical facilities located in Marlborough, Mass. and Glens Falls, N.Y. in 2014. The matters raised in the Warning Letter and observations focused on design control processes related to packaging validations and accelerated and real time aging testing in connection with the Company's fluid management and PICC families of products, inconsistency of a manufacturing product test process used among similar valved PICC products, a particular verification test of valved PICC products and non-conforming product control procedures. The Company takes these matters seriously and is committed to complying with all applicable laws, regulations and rules in connection with the manufacturing, sale and marketing of its products. The Company made a comprehensive response to the issues raised in the letter and is committed to working with FDA to resolve all outstanding issues.
  • The Company saw regulatory developments in both domestic and international registrations and renewals. Recent U.S. approvals include two new FDA clearances for the AngioVac system updating the cannula design for improved vessel access and changes to the circuit to improve rapid connector set up. In addition the packaging for the system has been updated for easier access and storage. Other U.S. clearances included a VenaCure EVLT NeverTouch Procedure Kit and Tre-Sheath and PICC Maximal Barrier Nursing Kit. Internationally, the Company gained NanoKnife registrations in New Zealand, Russia, Thailand and Hong Kong, as well as radio frequency ablation registrations in Israel and microwave in Thailand, along with various Vascular Access and Peripheral vascular registrations in Canada, Europe, Israel and China.
  • AngioDynamics saw further clinical traction with NanoKnife, with two new papers published during the course of quarter. This included, "Systematic review of irreversible electroporation in the treatment of advanced pancreatic cancer," published by EJSO online in August 2014 by Dr. Moir et al., and, "Irreversible Electroporation: A Novel Therapy for Stage III Pancreatic Cancer," published by Advances in Surgery online in September 2014 by Dr. Weiss and Wolfgang from Johns Hopkins' Department of Surgery.

Six Months Financial Results

For the six months ended November 30, 2014, net sales were $179.5 million, a 4% increase compared to the $172.2 million reported a year ago. The Company's net income was $1.8 million, or $0.05 per share, compared to net loss of $0.6 million, or $0.02 per share, reported a year ago. Excluding the items shown in the attached quarterly non-GAAP reconciliation table, adjusted net income was $11.9 million, or $0.33 per share, compared to net income of $8.9 million, or $0.25 per share, a year ago, representing a 32% increase. EBITDA was $21.8 million, or $0.61 per share, compared to EBITDA of $16.7 million, or $0.47 per share, a year ago. Adjusted EBITDA, excluding the items shown in the attached reconciliation table, was $30.4 million, or $0.84 per share, compared to $25.6 million, or $0.73 per share, in the year ago period, representing a 19% increase.

Fiscal 2015 and Third Quarter Guidance

"As a result of our continued strong operational performance, we are raising both the lower and upper end of our adjusted earnings per share (EPS) guidance to a range of $0.66 to $0.72," said Mark Frost, Executive Vice President and Chief Financial Officer, "while maintaining our net sales guidance range at $362 million to $368 million.

"We are anticipating net sales to range from $88 million to $91 million in the third quarter, 5% at the top end excluding our supply agreement," Mr. Frost continued. "Adjusted EPS excluding amortization is expected to be $0.14 to $0.17, representing a 21% improvement over third quarter fiscal 2014 at the high end."

Conference Call

AngioDynamics will host a conference call today at 4:30 p.m. Eastern Time to discuss its second quarter results. To participate in the live call by telephone, please call 1-888-299-7209 and reference the Conference ID: 2628397. In addition, a live webcast and archived replay of the call will be available at http://investors.angiodynamics.com. To access the live webcast, please go to the website 15 minutes prior to its start to register, download and install the necessary software.

Use of Non-GAAP Measures

Management uses non-GAAP measures to establish operational goals, and believes that non-GAAP measures may assist investors in analyzing the underlying trends in AngioDynamics' business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. In this news release, AngioDynamics has reported net sales, excluding a supply agreement; EBITDA (income before interest, taxes, depreciation and amortization); adjusted EBITDA; adjusted net income and adjusted earnings per share. Management uses these measures in its internal analysis and review of operational performance. Management believes that these measures provide investors with useful information in comparing AngioDynamics' performance over different periods. By using these non-GAAP measures, management believes that investors get a better picture of the performance of AngioDynamics' underlying business. Management encourages investors to review AngioDynamics' financial results prepared in accordance with GAAP to understand AngioDynamics' performance taking into account all relevant factors, including those that may only occur from time to time but have a material impact on AngioDynamics' financial results. Please see the tables that follow for a reconciliation of non-GAAP measures to measures prepared in accordance with GAAP.

About AngioDynamics

AngioDynamics Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics' diverse product lines include market-leading ablation systems, fluid management systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products and venous products. More information is available at www.AngioDynamics.com.


AngioDynamics, the AngioDynamics logo, AngioVac, BioFlo, NanoKnife, NeverTouch, Tre-Sheath and VenaCure EVLT are trademarks and/or registered trademarks of AngioDynamics Inc., an affiliate or a subsidiary. Celerity is a trademark and/or registered trademark of Medical Components Inc.

Safe Harbor

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics' expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate purchased businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2014, its Annual Report on Form 10-K/A for the fiscal year ended May 31, 2014, and its quarterly report on form 10-Q for the fiscal quarter ended August 31, 2014, and the current reports on Form 8-K, filed with the SEC on October 9, 2014, Oct. 31, 2014, and November 14, 2014. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

In the United States, the NanoKnife System has received a 510(k) clearance by the Food and Drug Administration for use in the surgical ablation of soft tissue, and is similarly approved for commercialization in Canada, the European Union and Australia. The NanoKnife System has not been cleared for the treatment or therapy of a specific disease or condition.

(in thousands, except per share data)
  Three months ended Six months ended
  Nov 30, Nov 30, Nov 30, Nov 30,
  2014 2013 2014 2013
  (unaudited) (unaudited)
Net sales $ 92,149 $ 88,571 $ 179,480 $ 172,215
Cost of sales  44,493  43,686  85,999  84,750
Gross profit  47,656  44,885  93,481  87,465
% of net sales 51.7% 50.7% 52.1% 50.8%
Operating expenses        
Research and development   6,069  7,003  12,787  13,712
Sales and marketing  20,981  21,073  41,048  41,036
General and administrative  7,973  6,411  15,296  13,097
Amortization of intangibles  4,063  4,339  8,078  8,448
Medical device tax  1,076  999  2,071  1,975
Change in fair value of contingent consideration  617  940  1,418  1,673
Acquisition, restructuring and other  2,302  2,679  4,966  4,681
Total operating expenses  43,081  43,444  85,664  84,622
Operating income   4,575  1,441  7,817  2,843
Other income (expense), net  (1,745)  (1,791)  (3,569)  (3,756)
Income (loss) before income taxes  2,830  (350)  4,248  (913)
Provision for (benefit from) income taxes  1,492  (89)  2,440  (279)
Net income (loss)  $ 1,338  $ (261)  $ 1,808  $ (634)
Earnings (loss) per common share        
Basic  $ 0.04  $ (0.01)  $ 0.05  $ (0.02)
Diluted  $ 0.04  $ (0.01)  $ 0.05  $ (0.02)
Weighted average common shares        
Basic  35,595  35,132  35,475  35,041
Diluted  36,127  35,132  36,012  35,041
(in thousands, except per share data)
Reconciliation of Net Income to non-GAAP Adjusted Net Income:
  Three months ended Six months ended
  Nov 30, Nov 30, Nov 30, Nov 30,
  2014 2013 2014 2013
  (unaudited) (unaudited)
Net income (loss)  $ 1,338  $ (261)  $ 1,808  $ (634)
Amortization of intangibles  4,063  4,339  8,078  8,448
Change in fair value of contingent consideration  617  940  1,418  1,673
Amortization of inventory basis step-up (1)  --   75  --   75
Acquisition, restructuring and other (2)  2,302  2,679  4,966  4,681
Tax effect of non-GAAP items (3)  (2,089)  (2,893)  (4,389)  (5,376)
Adjusted net income  $ 6,231  $ 4,879  $ 11,881  $ 8,867
Reconciliation of Diluted Earnings Per Share to non-GAAP Adjusted Diluted Earnings Per Share:
  Three months ended Six months ended
  Nov 30, Nov 30, Nov 30, Nov 30,
  2014 2013 2014 2013
  (unaudited) (unaudited)
Diluted earnings (loss) per share  $ 0.04  $ (0.01)  $ 0.05  $ (0.02)
Amortization of intangibles  0.11  0.12  0.22  0.24
Change in fair value of contingent consideration  0.02  0.03  0.04  0.05
Amortization of inventory basis step-up (1)  --   0.00  --   0.00
Acquisition, restructuring and other (2)  0.06  0.08  0.14  0.13
Tax effect of non-GAAP items (3)  (0.06)  (0.08)  (0.12)  (0.15)
Adjusted diluted earnings per share  $ 0.17  $ 0.14  $ 0.33  $ 0.25
Adjusted diluted sharecount  35,947  35,348  36,012  35,216
(1) Amortization of step-up of acquired inventory value in accounting for acquisitions.
(2) Includes costs related to acquisitions, integrations, restructurings, debt refinancings, litigation, and other items.
(3) Represents the net tax effect of non-GAAP adjustments.
(in thousands, except per share data)
Reconciliation of Net Income to EBITDA and Adjusted EBITDA:
  Three months ended Six months ended
  Nov 30, Nov 30, Nov 30, Nov 30,
  2014 2013 2014 2013
  (unaudited) (unaudited)
Net income (loss)  $ 1,338  $ (261)  $ 1,808  $ (634)
Provision for (benefit from) income taxes  1,492  (89)  2,440  (279)
Other income (expense), net  1,745  1,791  3,569  3,756
Depreciation and amortization  7,314  7,123  13,999  13,870
EBITDA  11,889  8,564  21,816  16,713
Change in fair value of contingent consideration  617  940  1,418  1,673
Amortization of inventory basis step-up (1)  --   75  --   75
Acquisition, restructuring and other (2,3)  1,927  2,679  4,216  4,681
Stock-based compensation  1,506  1,271  2,901  2,423
Adjusted EBITDA  $ 15,939  $ 13,529  $ 30,351  $ 25,565
Per diluted share:        
EBITDA  $ 0.33  $ 0.24  $ 0.61  $ 0.47
Adjusted EBITDA  $ 0.44  $ 0.38  $ 0.84  $ 0.73
(1) Amortization of step-up of acquired inventory value in accounting for acquisitions.
(2) Includes costs related to acquisitions, integrations, restructurings, debt refinancings, litigation, and other items.
(3) Excludes depreciation expense captured in the depreciation and amortization component of the reconciliation.
(unaudited in thousands)
  Three months ended (a) Six months ended (b)
  Nov 30, Nov 30, % Nov 30, Nov 30, %
  2014 2013 Growth 2014 2013 Growth
Net Sales by Product Category            
Peripheral Vascular $ 49,441 $ 48,815 1% $ 96,802 $ 94,360 3%
Vascular Access  27,968  25,571 9%  54,393  50,854 7%
Oncology/Surgery  13,634  12,557 9%  25,996  23,724 10%
Total Excluding Supply Agreement  91,042  86,943 5%  177,190  168,938 5%
Supply Agreement  1,107  1,628 -32%  2,290  3,277 -30%
Total $ 92,149 $ 88,571 4% $ 179,480 $ 172,215 4%
Net Sales by Geography            
United States $ 72,059 $ 69,485 4% $ 140,438 $ 136,652 3%
International  18,984  17,458 9%  36,752  32,286 14%
Supply Agreement  1,107  1,628 -32%  2,290  3,277 -30%
Total $ 92,149 $ 88,571 4% $ 179,480 $ 172,215 4%
(a) There were 62 sales days in the three months ended November 30, 2014 and 2013.
(b) There were 126 sales days in the six months ended November 30, 2014 and 2013.
(in thousands)
  Nov 30, May 31, 
  2014 2014
  (unaudited) (unaudited)
Current Assets    
Cash and cash equivalents $ 14,877 $ 16,105
Marketable securities  1,698  1,809
Total cash and investments  16,575  17,914
Receivables, net  58,556  61,968
Inventories, net  75,315  61,234
Deferred income taxes  4,091  4,625
Prepaid income taxes  2,156  510
Prepaid expenses and other  6,753  5,471
Total current assets  163,446  151,722
Property, plant and equipment, net  67,553  66,590
Intangible assets, net  197,362  205,256
Goodwill  360,473  360,473
Deferred income taxes  7,236  10,403
Other non-current assets  3,260  4,447
Total Assets $ 799,330 $ 798,891
Liabilities and Stockholders' Equity    
Accounts payable and accrued expenses $ 41,146 $ 49,547
Current portion of long-term debt  6,250  5,000
Current portion of contingent consideration  9,795  10,918
Other current liabilities  746  1,288
Total current liabilities  57,937  66,753
Long-term debt, net of current portion  148,910  137,660
Contingent consideration, net of current portion  47,643  56,413
Other long-term liabilities  1,270  1,230
Total Liabilities  255,760  262,056
Stockholders' equity  543,570  536,835
Total Liabilities and Stockholders' Equity $ 799,330 $ 798,891
(in thousands)
  Three months ended Six months ended
  Nov 30, Nov 30, Nov 30, Nov 30,
  2014 2013 2014 2013
  (unaudited) (unaudited) (unaudited) (unaudited)
Cash flows from operating activities:        
Net income (loss)   $ 1,338  $ (261)  $ 1,808  $ (634)
Depreciation and amortization   7,314  7,123  13,999  13,870
Amortization of acquired inventory basis step-up   --   75  --   75
Change in fair value of contingent consideration   617  940  1,418  1,673
Tax effect of exercise of stock options   --   (85)  --   (146)
Deferred income taxes   1,575  586  3,685  1,155
Stock-based compensation   1,506  1,271  2,901  2,423
Other   (61)  140  256  288
Changes in operating assets and liabilities         
Receivables   (2,746)  (1,916)  3,069  (123)
Inventories   (4,894)  (878)  (14,081)  (4,351)
Accounts payable and accrued liabilities   (5,905)  2,133  (6,138)  3,410
Other   (891)  (670)  (3,712)  (1,882)
Net cash provided by (used in) operating activities   (2,147)  8,458  3,205  15,758
Cash flows from investing activities:         
Additions to property, plant and equipment   (2,419)  (4,288)  (7,523)  (7,191)
Acquisition of businesses, net of cash acquired   --   --   --   (4,169)
Acquisition of intangible assets   (96)  (150)  (250)  (150)
Other cash flows from investing activities   --   --   --   303
Net cash provided by (used in) investing activities   (2,515)  (4,438)  (7,773)  (11,207)
Cash flows from financing activities:        
Repayment of long-term debt   (1,250)  (143,750)  (2,500)  (143,750)
Proceeds from issuance of long-term debt and revolver borrowings   15,000  141,410  15,000  141,410
Payment of Contingent Consideration   (9,122)  (8,350)  (11,222)  (9,300)
Proceeds from exercise of stock options and ESPP   1,144  455  2,103  1,133
Other cash flows from financing activities   --   (677)  --   (677)
Net cash provided by (used in) financing activities   5,772  (10,912)  3,381  (11,184)
Effect of exchange rate changes on cash   (41)  --   (41)  4
Increase (Decrease) in cash and cash equivalents   1,069  (6,892)  (1,228)  (6,629)
Cash and cash equivalents        
Beginning of period   13,808  22,065  16,105  21,802
End of period  $ 14,877 $ 15,173 $ 14,877 $ 15,173


Sign up for e-news

In the News (Homepage Include)

1.8.2015 - AngioDynamics Reports 2015 Second Quarter Financial Results


06.13.2011 - AngioDynamics Reports Preliminary Fiscal 2011 Fourth Quarter Financial Results and Corporate Developments

Sign up for e-news

Privacy Policy


AngioDynamics, Inc. (ADI) is dedicated to keeping the information you choose to share with us through the web sites (Sites) owned and/or operated by us secure. Ensuring your understanding of how we use and maintain your information is important to ADI. To that end, we have provided below our General Policy and our Registered User Requirements and Information.

Note: for purposes of this Privacy Policy, when we use the term "your information" or similar terms, we mean information personally identifiable with a specific user of our Sites or about a user's current or former relationship with ADI or any of its subsidiaries or affiliates.

This Privacy Policy discloses our privacy practices as to:

  • collection and use of information provided by you.
  • the privacy protection mechanisms we have implemented; and
  • how you can access, update or delete any information provided by you.

If you have any questions concerning our Privacy Policy, what information about you we collect and use, or if you do not understand any of the terms or disclosures noted below, you may contact us at info@angiodynamics.com.

I. General Policy.

ADI maintains physical, electronic and procedural safeguards to protect your information. Though no data transmission over the Internet is 100% secure from intrusion, we have used and will continue to use reasonable efforts to ensure the protection of your information. We assess new technology for protecting information and, when appropriate, upgrade our information security systems.

We collect information about you when you visit and use the Sites and when you enter or input information.

You can visit the Sites and learn about our company, products and services, and find out how to contact us without giving us any personal information about yourself. If we request personally identifiable information, you may decline to provide such and thus opt out of receiving future communications from us.

We may use information about you to inform us on how best to update the Sites and enhance the experience for such visitors. Personally identifiable information is not extracted for this purpose. We use such information on an aggregated basis to help us operate the Sites, enhance and improve our service, improve the look of the Sites and display advertising and marketing information. We may use personally identifiable information to display content we think will be of interest to you, or to customize what you see when you visit the Sites.

The information we may collect and store generally consists of information gathered from your registration, data input, forms and other information you provide us, electronically, by phone, in writing, in person or by any other means and information about your transactions and experience with ADI, such as account balances and purchasing activity.

Information is critical to our ability to provide high quality service to you, but the trust that you place in how we provide that service is an important asset. Keeping your information secure is a top priority for all of us at ADI. Consequently, our privacy standards are designed to ensure that we will:

  • collect and use only the necessary information required for us to deliver high quality service, to administer our business and to let you know of products and services that are available from our family of companies;
  • protect the information you share with us, maintaining strict standards of security and confidentiality;
  • not disclose information, personal or business, to any external organization in a manner not otherwise contemplated herein unless we have previously notified you (or the business, in the case of a commercial enterprise) and obtained your consent or if we enter into a specific agreement with you;
  • require any other organization that we retain or engage to provide support services for us to conform to our privacy standards.

Your privacy is important to us. However, there are legal and technical reasons why we cannot fully ensure that your personally identifiable information will be kept confidential at all times. For example, we may be compelled to disclose your information to a governmental agency or a court; or third parties may unlawfully intercept or access transmissions or private communications. Additionally, we may (and you hereby authorize us to do so) disclose any information about you to private entities, law enforcement or other government officials as we, in our sole discretion, believe necessary or appropriate to investigate or resolve possible problems or inquiries or to protect our own business and assets. In such circumstances, we will, where possible, require such third parties to maintain the confidentiality of any information so disclosed.

ADI may change this Privacy Policy from time to time. Any changes will be effective immediately upon posting to the Sites. Please check back regularly to ensure you read and understand our current privacy practices

II. Registered User Requirements And Information

Some features on the Sites may require you to register in order to get our authorization before you can use those features. Whether you are an individual or a corporation, partnership or other form of commercial enterprise, in order for you to obtain our authorization to use those features and be considered a registered user, you must provide us with certain information about you and your business and, for security purposes, we may require some personal information about you and, if you represent a business, we may request personal information about those you designate to represent that business.

If you are a registered user, you acknowledge and also consent to our tracking your activities and use of the Sites in connection with the non-public functions of the Sites, such as confirming and filling orders, maintaining quality control and contacting you concerning your orders, transactions or subscription.

In addition to information about your business, for security purposes, we require that you provide us with information such as names, addresses, e-mail addresses, telephone numbers and other personally identifiable information for each individual who will use the Sites, in order for us to authorize you and those individuals to access the features of the Sites that are available only to registered users. This information also helps us to ensure we are able to securely identify you and each of these individuals as authorized users for the features you have successfully registered to use. Once registration is complete and we have granted you authorization, we will provide you with a user identification number and allow you to select a unique user ID and password. You will be able to change your password, as well as any personal data you have given us in order to update your information. If you are a designated representative of a business, keep in mind that an authorized representative of the business will also have the right to revoke that designation and, if so notified, we will immediately terminate your right to use the Sites.

When you submit personally identifiable information on behalf of others, you represent that you have their authorization to provide this information to us. We reserve the right to (i) ask you to provide evidence of that authorization at any time during or after the submission process and (ii) contact those individuals to confirm the authorization. If we determine that such authorization has not been properly obtained, we may immediately and without notice, discontinue your authorization to use the Sites.

Submitting information to us is not a guarantee or assurance that we will grant authorization or permit you, or anyone you designate, to use any or all of the features of the Sites. If, for any reason, you are not granted authorization we will only retain the information you submit to us in order to communicate with you regarding your application and perhaps request additional or follow-up information, for audit purposes or as may be required by law or regulation and we will not use your information for any other purposes.

The personal information you provide and any data, personal or otherwise, that you disclose may be saved on the Sites for the following purposes:

(i) we may use such information to advise you of or provide additional information regarding products or services that may be available through ADI or its affiliates;

(ii) we may use such information and data to administer our business, the Sites, and our services in a manner consistent with the Terms of Use that govern your use of the Sites as well as all applicable laws, rules, regulations and other legal obligations; and

(iii) we may disclose such information to third party physicians and health care providers who purchase our products and services for the benefit of their respective patients for the sole purpose of contacting you directly regarding the same, unless you indicate to us via the Site or otherwise in writing that you wish to opt out of such disclosures. Except as set forth above, we do not sell or market your personal information or personalized data to unaffiliated organizations. If you provide us with your email address, we may occasionally send you e-mail and any e-mail sent to us by you through the Sites will be handled and maintained in accordance with the legal and regulatory requirements we must comply with, if any, regarding communications from users and the public.

ADI may collect and use the information you provide to enable us to save you time and money by better understanding your needs so that we can provide you with more relevant information about ADI's products and services.

III. "Cookies"

Some of our Web Sites will send a "cookie," a small text file, to your computer. This allows us to recognize your computer the next time you visit, without bothering you with another request to register. If you do not wish to receive cookies, please refer to the "Help" file of your Internet Browser to learn how to either block all cookies or receive a warning before a cookie is stored. To learn more about cookies we encourage you to visit www.cookiecentral.com If you visit our Web Sites to browse, read, or download information, we collect and store some "visitor information" from you, such as the name of the domain and host from which you access the Internet, the Internet Protocol (IP) address of the computer you are using, the date and time you access our Web Site, and the Internet address of the website from which you linked directly to our Web Site. We use this information to measure the traffic on our Web Sites and to help us make our Web Sites more useful. We delete this information after some time

IV. Information About Minors

ADI's Web Sites are generally not targeted at children under the age of fourteen. We will not knowingly collect information from site visitors in this age group. We encourage parents and legal guardians to monitor their children's Internet usage and to help enforce our Privacy Policy by instructing their children to never provide Personal Information on this Site without their permission.

V. Links to Other Sites

As a resource to our visitors, ADI may provide links to other Internet sites. Please be aware that we do not control other Internet sites and that, in any case, this Internet Privacy Policy does not apply to those Internet sites. We encourage you to read the privacy policy of every Internet site you visit.

VI. Anti-Spam Policy

ADI does not distribute or sell customers' confidential information from our opt-in lists.

Definition of Spam from MAPS – Mail Abuse Prevention System
An email is spam if:

  1. The recipient's personal identity and context are irrelevant because the message is equally applicable to many other potential recipients; AND
  2. The recipient has not verifiably granted deliberate, explicit, and still-revocable permission for it to be sent; AND
  3. The transmission and reception of the message appears to the recipient to give a disproportionate benefit to the sender.

ADI's Commitment:

  • AngioDynamics DOES NOT send out unsolicited email (UCE/Spam) (Please note UCE stands for unsolicited commercial email)
  • AngioDynamics DOES NOT knowingly do business with any company that participates in sending UCE/SPAM
  • AngioDynamics DOES NOT sell or exchange personal information from our opt-in lists.

Rev. December 16, 2009

Sign up for e-news

A Global Reach, A Community Presence

During the last 25 years, AngioDynamics has grown to have a global reach, with facilities in three U.S. states, The Netherlands, Hong Kong, Germany and Great Britain. The company has its Corporate Headquarters in Albany, N.Y., U.S., and continues to have a major presence in Queensbury, N.Y., U.S., and Glens Falls, N.Y., where it designs, develops and manufactures many of its products. The manufacturing of AngioDynamics’ port systems, electrosurgical devices and needle sets occurs at its Manchester, Ga., U.S., facility, while cutting-edge research and development is performed in Marlborough, Mass., U.S. The company also has opened an International Headquarters in Amsterdam, The Netherlands, and sales offices in Hong Kong and Hamburg, Germany, as well as a facility in Denmead, U.K., focused on the manufacture of its microwave ablation systems.

New York – Global Headquarters 
14 Plaza Drive
Latham, N.Y. 12110 USA
Phone: 1-800-772-6446
+1 (518) 795-1400
Fax: +1 (518) 795-1401

Airport: Albany International Airport (ALB)
Holiday Inn Express & Suites Latham
400 Old Loudon Road
Latham, NY 12110
(Closest to the Global Headquarters.)

Hotel Indigo
254 Old Wolf Road
Latham, NY,12110
(Closest to the Albany Airport.)

New York – Queensbury Manufacturing Facility
603 Queensbury Ave.
Queensbury, NY, 12804 USA
Phone: 1-800-772-6446
+1 (518) 798-1215
Fax: +1 (518) 798-3625

Airport: Albany International (ALB)

Comfort Suites Lake George
1533 State Route 9
Lake George, NY 12845 
(Closest to facility) 

Hampton Inn & Suites 
25 Lake Avenue
Saratoga Springs, NY 12866
(Within walking distance to restaurants and night life; approximately 30 minutes from facility) 

New York - Glens Falls Manufacturing Facility
10 Glens Falls Tech Park
Glens Falls, NY 12801
Phone: 1-800-772-6446
+1 (518) 742-4495
Fax: 518-798-3625

Airport: Albany International (ALB)

Comfort Suites Lake George
1533 State Route 9
Lake George, NY 12845 
(Closest to facility) 

Hampton Inn & Suites 
25 Lake Avenue
Saratoga Springs, NY 12866
(Within walking distance to restaurants and night life; approximately 30 minutes from facility) 

1 Horizon Way
Manchester, GA, 31816 USA

Airport: Atlanta (ATL)

Best Western White House Inn
2526 White House Pkwy
Warm Springs, GA 31830
(Closest to facility)

Springhill Suites Newnan
1119 Bullsboro Drive
Newnan, GA 30265
(Closest to restaurants; about 50 miles from facility)

26 Forest Street
Marlborough, MA 01752
Phone: 1-877-658-7990

Airport: Logan (BOS)

The Netherlands
AngioDynamics Netherlands BV
Haaksbergweg 75 (Margriettoren)
1101 BR Amsterdam Z-O

Amsterdam Schipol, 13 miles from facility

Hotel JL no 76
Jan Luijckenstraat 76  
1071 CT Amsterdam   
The Netherlands

Hotel Vondel
Vondelstraat 26
1054 GD Amsterdam
The Netherlands

Hong Kong
Suite 6, 6/F Luk Kwok Centre
72 Gloucester Road, Wan Chai
Hong Kong SAR

Hong Kong International, 25 miles from facility

Halenreie 42
22359 Hamburg-Volksdorf | Germany

Hamburg Airport – ca. 15km/ 30min

Hotel du Nord, Im Alten Dorfe 40, Hamburg, Germany

United Kingdom
1 Falcon Court
Parklands Business Park
Hampshire, PO7 6XP
United Kingdom



Portsmouth Marriott Hotel
Southampton Road
Portsmouth,  PO6 4SH
United Kingdom
Phone: 44-23-9238 3151
Fax: 44-23-9238 8701

Sign up for e-news

Patient Resources

At AngioDynamics we are focusing on patient care every day, but we understand that undergoing a procedure is not an everyday occurrence for most patients. You probably have a lot of questions, and we hope that the materials on this page will help answer some of the most common questions about our products and your upcoming procedure. Additionally, we have listed links to the Web sites of several organizations below that you may find helpful during your journey. Please remember these are only tools, and that your physician is best suited to answer your questions.

National Cancer Institute
American Academy of Dermatology
American Cancer Society
American Academy of Family Physicians
Mayo Clinic
Society of Interventional Radiology
American College of Phlebology
VenaCure EVLT™
American Venous Forum
Vascular Disease Foundation


To provide benefits to patients by being the leader in design, development, manufacturing and marketing of innovative, proprietary, therapeutic devices used by interventionalists and surgeons for the minimally invasive treatment of peripheral vascular disease, tumor therapy and other, non-vascular disease.


AngioDynamics is deeply committed to improving patient care by ethically serving its customers, shareholders and employees. We value the importance of trust and honesty in all of the relationships that we build. AngioDynamics is dedicated to its pursuit of innovation and tenaciously strives for continuous improvement in every area.

AngioDynamics seeks to add significant value in every interaction with its customers by providing unsurpassed service and the highest quality, best performing products. To accomplish this, AngioDynamics is committed to its employees receiving the highest level of training, and to providing an environment that promotes continual employee growth. All AngioDynamics employees constantly endeavor to be the best and the brightest in the medical device industry.

Sign up for e-news

About AngioDynamics

AngioDynamics® history is best characterized by innovation and growth. Originally founded in Queensbury, N.Y., U.S., in 1988, AngioDynamics® has grown into a NASDAQ-listed public company with a global reach.

Queensbury was chosen due to its location in the heart of “Catheter Valley,” an area in New York’s Adirondack Region named for its long history of catheter and other medical device manufacturing. Today, the Company has made its presence apparent far beyond Upstate New York with 1,400 employees worldwide at facilities in the United States, Europe and Asia. AngioDynamics is currently selling in more than 50 markets through direct sales and distributors.

Initially dedicated to the research and development of products used in interventional radiology, AngioDynamics began shipping product in the early 1990s. The Company soon became well established as a producer of diagnostic catheters for non-coronary angiography and thrombolytic delivery systems. In May 2004 the Company became publicly traded on the NASDAQ stock exchange under the symbol ANGO.

Through acquisitions of companies such as RITA Medical Systems in January 2007, Oncobionic in May 2008, and the assets of Diomed in June 2008 and FlowMedica in January 2009, AngioDynamics now boasts a diverse product line that includes market-leading radiofrequency ablation and NanoKnife® systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products, venous products and targeted renal therapy products.

Continuing its expansion, AngioDynamics opened a new headquarters in Albany, N.Y., in March 2010. Most recently, in May 2012, AngioDynamics acquired Navilyst Medical, bringing market-leading fluid management systems into its portfolio. The acquisition significantly expanded the Company’s scale, doubling its share of the vascular access market while building critical mass in the peripheral vascular market. A comprehensive look at the Company’s history can be found in the form of an interactive timeline of events at www.angiodynamics.com.

Sign up for e-news

Contact AngioDynamics

Please be advised, effective January 21st, 2014, AngioDynamics and Navilyst Medical will merge under one unified business information system. This will impact the way our customers order products. All products in the AngioDynamics portfolio will now have universal part numbers. To avoid business interruptions, please visit our resource materials, herein, for further information and updates required.
Corporate Office
14 Plaza Drive
Latham, NY 12110
Hours of Operation: 
8 a.m. to 5 p.m. ET
Tel: +1 518-795-1400
Fax: +1 518-795-1401
General e-mail: 

International Offices

Amsterdam Office

AngioDynamics Netherlands BV
Haaksbergweg 75 (Margriettoren)
1101 BR Amsterdam Z-O
Hours of Operation: 08.30 - 17.00 (Local)
Tel: +31 (0)20 753 2949
Fax: +31(0)20 753 2939
General e-mail:

U.S. Customer Service
603 Queensbury Ave.
Queensbury, NY 12804
Hours of Operation: 
8 a.m. to 6 p.m., Monday-Friday
Toll Free Telephone: 1-800-772-6446
(select option 2 for Customer Service)
Fax: +1 518-798-1360

Physician Clinical Product Questions
Contact our clinical specialists by calling 1-800-772-6446, option 5


Hong Kong Office
Suite 6, 6/F Luk Kwok Centre
72 Gloucester Road, Wan Chai
Hong Kong SAR
Hours of Operation:
Weekdays 09:00 - 18:00
Tel: +852 3127 5507
Fax: +852 3127 5656
General e-mail:

Hamburg Office
Halenreie 42
22359 Hamburg-Volksdorf | Germany
Tel: +49 (0) 40 85 41 37 90
Fax: +49 (0) 40 85 41 37 91-5
Email: hamburg@angiodynamics.com

1 Falcon Court
Parklands Business Park
Hampshire, PO7 6XP
United Kingdom
Phone: +44 (0)2392 240011
Fax: +44 (0)2392 240051

Investor Relations Contacts
EVC Group, Inc.
Christopher Dailey

Robert Jones
Customer Service International

GERMANY/DEUTSCHLAND (08:30 – 17:00 Local)
Rufnummer: 0800 180 8497 (Kostenlos)
Fax: 0800 100 3827 (Kostenlos)
E-mail: csinternational@angiodynamics.com
FRANCE (08:30 – 17:00 Local)
Téléphone: 0800 907 948 (numéro Vert - gratuit)
Fax: 0800 940 395 (numéro Vert - gratuit)
E-mail: csinternational@angiodynamics.com

NETHERLANDS/NEDERLAND (08:30 – 17:00 Local)
Telefoon: 0800 40 40 013 (Gratis)
Fax: 0800 40 40 014 (Gratis)
E-mail: csinternational@angiodynamics.com
UNITED KINGDOM (08:30 – 17:00 Local)
Telephone: 0808 234 7774 (UK Toll Free)
Fax: 0800 358 0866 (UK Toll Free)
E-mail: csinternational@angiodynamics.com

Telephone: +31 (0) 20 753 2949
Fax: +31 (0) 20 753 2939
E-mail: csinternational@angiodynamics.com

Sample Page

I'm now going to add a bunch of new content for the page.


Sign up for e-news